DDInter410 DDInter927
Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, clomipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as clomipramine, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic ser
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Clomipramine {u} (Compound) resembles {v} (Compound) Adinazolam
Clomipramine {u} (Compound) resembles {v} (Compound) Thioridazine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Clomipramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clofedanol
Clomipramine {u} (Compound) binds {v} (Gene) CYP1A2
Clomipramine {u} (Compound) upregulates {v} (Gene) TGFBR2
Clomipramine {u} (Compound) palliates {v} (Disease) panic disorder
Clomipramine {u} (Compound) causes {v} (Side Effect) Uterine haemorrhage
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Clomipramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ammonium chloride
Clomipramine (Compound) resembles Adinazolam (Compound)
Clomipramine (Compound) resembles Thioridazine (Compound)
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Clomipramine (Compound) binds CYP1A2 (Gene)
Clomipramine (Compound) upregulates TGFBR2 (Gene)
Clomipramine (Compound) palliates panic disorder (Disease)
Clomipramine (Compound) causes Uterine haemorrhage (Side Effect)
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Clomipramine may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride